

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number
WO 2005/016868 A2

- (51) International Patent Classification⁷: **C07C 235/00**
- (21) International Application Number:
PCT/EP2004/009087
- (22) International Filing Date: 12 August 2004 (12.08.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0319069.1 14 August 2003 (14.08.2003) GB
- (71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **HOLMES, Ian** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **WATSON, Stephen, Paul** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB).
- (74) Agent: **QUILLIN, Helen**; GlaxoSmithKline, Corporate Intellectual Property, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MATRIX METALLOPROTEINASE INHIBITORS



(57) Abstract: Compounds of Formula (I), wherein R¹ represents optionally substituted -C₄₋₁₂ alkyl, -C₂₋₁₀alkylcycloalkyl, -C₂₋₆ alkyl heterocycloalkyl, -C₂₋₆alkylaryl, optionally substituted 5- or 6- membered aryl or heteroaryl, except pyridinyl. Z represents a bond, CH₂, O, S, SO, SO₂, NR⁴, OCR⁴R⁵, CR⁴R⁵O, or Z, R¹ and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6- membered aryl or heteroaryl ring; X represents COR³; R² represents CONH₂, CO₂H, CO₂R⁷, SO₂R⁷ or SO₂NR⁸R⁹,

except that R²; may not represent CO₂R⁷ when X is CONH₂; R³ represents OR⁶, or NR⁸R⁹; R⁴ and R⁵ each independently represents H, C₁₋₆ alkyl or C₁₋₄ alkylaryl; R⁶ represents H or C₁₋₆ alkyl; R⁷ represents C₁₋₆ alkyl; R⁸ and R⁹ each independently represents H or C₁₋₆ alkyl or R⁸ and R⁹ together with the nitrogen atom to which they are attached form a 5- or 6- membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; and physiologically functional derivatives thereof with the exception of [3-(acetylamino)-4-cyclohexylphenyl]-butanedioic acid and 3-(acetylamino)-4-cyclohexylphenyl]-butanedioic acid diethyl ether; butanedioic acid [3-methoxy-4-(phenylmethoxy)phenyl]; butanedioic acid [4-(phenylmethoxy)phenyl]; with the proviso that when R¹ represents C₄₋₁₂ alkyl, Z is other than a bond, O or CH₂; and physiologically functional derivatives thereof, processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metalloproteinase enzymes (MMPs) are described.